The European Patent Office (EPO) has officially granted patent EP3604503B1, titled 'Additive for undifferentiation maintaining medium'. This patent, effective March 18, 2026, covers a specific additive designed for use in media that maintain cellular undifferentiation. The grant signifies the EPO's recognition of the invention's novelty and inventiveness within the biotechnology sector.

This patent grant primarily impacts entities involved in biotechnology research and development, particularly those working with cell culture and regenerative medicine. While this is a patent grant and not a regulatory rule imposing direct compliance obligations, it establishes intellectual property rights that may affect market exclusivity and freedom to operate for competitors in the designated European states. Companies in this space should be aware of this granted patent when developing or commercializing related products or processes.